Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Arthritis & Rheumatism

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ART.1780390105PMID 8546736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• DC-ART: what proportion of response constitutes a positive response?

  1994cited by this paper
• A simple index to assess disease activity in rheumatoid arthritis.

  1993cited by this paper
• A simple index to assess disease activity in rheumatoid arthritis.

  1993cited by this paper
• A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis.

  1993cited by this paper
• The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis.

  1993cited by this paper
• Outcome measures in rheumatoid arthritis clinical trials: assessing improvement.

  1993cited by this paper
• Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology.

  1993cited by this paper
• Sensitivity to change of rheumatoid arthritis clinical trial outcome measures.

  1993cited by this paper
• Low-dose prednisone in rheumatoid arthritis patients: placebo treatment?

  1991cited by this paper
• Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine.

  1990cited by this paper
• Can we develop simple response criteria for slow acting antirheumatic drugs?

  1990cited by this paper
• Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials.

  1990cited by this paper
• Response criteria for slow acting antirheumatic drugs.

  1990cited by this paper
• Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

  1990cited by this paper
• Sensitivity of a Dutch Health Assessment Questionnaire in a Trial Comparing Hydroxychloroquine vs. Sulphasalazine

  1990cited by this paper
• Rheumatology

  1990cited by this paper
• Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group.

  1990cited by this paper
• A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.

  1989cited by this paper
• Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.

  1989cited by this paper
• What are the 'best' measurements for monitoring patients during short-term second-line therapy?

  1988cited by this paper
• Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial.

  1986cited by this paper
• A methodologic framework for developing and selecting endpoints in clinical trials.

  1982cited by this paper
• A Mixed-longitudinal, interdisciplinary study of growth and development

  1979cited by this paper
• Letter: Moorgate tube disaster: disputed alcohol findings.

  1975cited by this paper
• Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

  1968cited by this paper
• 1958 Revision of diagnostic criteria for rheumatoid arthritis.

  1959cited by this paper

• Early Erythrocyte Methotrexate Polyglutamate-4 Predicts Treatment Response and Is Influenced by GGH 401C>T Genotype in Patients with Rheumatoid Arthritis

  2026cites this paper
• Blood-based gene signatures associated with therapeutic response to anti-TNF therapy in rheumatoid arthritis: a combined meta-analytical and machine learning approach

  2026cites this paper
• Comparative Effectiveness of Abatacept Versus Adalimumab in Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis

  2025influential citation
• Macrophage-Targeted [11C]DPA-713 PET/CT Imaging for Early Therapeutic Evaluation of Anti–Tumor Necrosis Factor Treatment in Rheumatoid Arthritis

  2025cites this paper
• Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

  2025cites this paper
• PD1+ innate lymphoid cells 3 predict JAK-dependent inflammation in rheumatoid arthritis.

  2025cites this paper
• CXCL13 as a Predictive Biomarker for Response to Methotrexate Monotherapy in Rheumatoid Arthritis

  2025cites this paper
• Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy

  2025cites this paper
• Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

  2025cites this paper
• Rheumatoid arthritis-associated interstitial lung disease in countries across the world.

  2025cites this paper
• Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.

  2025cites this paper
• Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation

  2025cites this paper
• Identification of Disulfidptosis-Related Genes and Molecular Subgroups in Rheumatoid Arthritis for Diagnostic Model and Patient Stratification

  2025cites this paper
• Pre-eclampsia is more common in women with active psoriatic arthritis in pregnancy: a population-based study

  2025cites this paper
• Clinical and laboratory predictors of therapeutic response to Tocilizumab in rheumatoid arthritis

  2025cites this paper
• Advances in treatment of psoriatic arthritis: current guidelines and emerging therapies.

  2025cites this paper
• Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.

  2025cites this paper
• Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients

  2025cites this paper
• Factors associated with pulmonary function decline in patients with rheumatoid arthritis-associated interstitial lung disease.

  2025cites this paper
• Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

  2024cites this paper
• Patient Reported Outcomes for SB5, an adalimumab biosIMILAR, in patients with rheumatoid arthritis and ankylosing spondylitis (PRO-SIMILAR): Study protocol for a phase IV, single-arm, open-label trial

  2024cites this paper
• Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy

  2024cites this paper
• Artificial intelligence as an assistant for studying treatment response in rheumatoid arthritis.

  2024cites this paper
• Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis

  2024cites this paper
• The kynurenine pathway in patients with rheumatoid arthritis during tumor necrosis factor α inhibitors treatment

  2024cites this paper
• Remission Is the Mission in Gout

  2024cites this paper
• Analysis of periodontal status in Polish patients with rheumatoid arthritis treated with biological therapies

  2024cites this paper
• Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial

  2024cites this paper
• Efficacy and safety of subcutaneous golimumab in patients with rheumatoid arthritis in a sample of Syrian patients: a cohort study

  2024cites this paper
• Recent advances in nuclear medicine and their role in inflammatory arthritis: focus on the emerging role of FAPI PET/CT

  2024cites this paper
• Predictors of Drug Retention and Survival Rate of bDMARDs in Rheumatoid Arthritis: A Four-Year Real-Life Tunisian Experience

  2024cites this paper
• Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients.

  2024cites this paper
• Adding ultrasound to treat-to-target shows no benefit in achieving clinical remission nor in slowing radiographic progression in rheumatoid arthritis: results from a multicenter prospective cohort

  2024cites this paper
• Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5

  2024cites this paper
• Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition

  2024cites this paper
• A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease

  2024cites this paper
• External Validation of the Machine Learning-Based Thermographic Indices for Rheumatoid Arthritis: A Prospective Longitudinal Study

  2024cites this paper
• Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity

  2024cites this paper
• Oxidative DNA Damage and Zinc Status in Patients With Rheumatoid Arthritis in Duhok, Iraq

  2024cites this paper
• Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study

  2024cites this paper
• Associations of genetic polymorphisms with clinical response to tocilizumab in Chinese rheumatoid arthritis patients.

  2024cites this paper
• PREDICTORS OF RHEUMATOID ARTHRITIS FLARE AFTER GLUCOCORTICOIDS WITHDRAWAL WHILE RECEIVING CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

  2024cites this paper
• Preterm birth, preeclampsia, gestational hypertension and offspring birth weight in women with active juvenile idiopathic arthritis and healthy controls

  2024cites this paper
• Radiological Progression and Predictors of Radiological Progression in Early Rheumatoid Arthritis Treated with Conventional Synthetic Disease-modifying Agents

  2024cites this paper
• Differences in referral path, clinical and radiographic outcomes between seronegative and seropositive rheumatoid arthritis Mexican Mestizo patients: A cohort study

  2024cites this paper
• Psychological distress over 12 months post-diagnosis in an early inflammatory arthritis cohort

  2024influential citation
• Evaluation of the efficacy and safety of a herbal formulation for rheumatoid arthritis - A non-inferiority randomized controlled trial.

  2024cites this paper
• Discontinuation of biologic and target-specific therapy in patients with rheumatoid arthritis: a retrospective cohort study

  2024cites this paper
• Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

  2024cites this paper
• Baseline ANA and Anti‐Ro60/SSA Antibody as Potential Predictors for Immunogenicity and Poor EULAR Response in Adalimumab‐Treated RA Patients

  2024cites this paper
• Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis

  2024cites this paper
• Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling

  2024cites this paper
• Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

  2024cites this paper
• Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM.

  2023cites this paper
• What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs?

  2023cites this paper
• Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis

  2023cites this paper
• AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double‐blind, efficacy, and safety study

  2023cites this paper
• Sialic-Acid-Related Enzymes of B Cells and Monocytes as Novel Markers to Discriminate Improvement Categories and to Fulfill Two Remission Definitions in Rheumatoid Arthritis

  2023cites this paper
• Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

  2023cites this paper
• The prognostic value of whole-genome DNA methylation in response to Leflunomide in patients with Rheumatoid Arthritis

  2023cites this paper
• A population-based study of caesarean section in women with juvenile idiopathic arthritis

  2023cites this paper
• The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

  2023cites this paper
• Preclinical Characterization of Pharmacologic NAD+ Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis

  2023cites this paper
• 68Ga-FAPI PET/CT for Rheumatoid Arthritis: A Prospective Study.

  2023cites this paper
• Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis

  2023cites this paper
• Caesarean section in women with axial spondyloarthritis and psoriatic arthritis: a population-based study

  2023cites this paper
• Efficacy and gastrointestinal tolerability of methotrexate in late-onset rheumatoid arthritis patients: a prospective cohort study

  2023cites this paper
• Management of Rheumatoid Arthritis With a Digital Health Application

  2023cites this paper
• Utilising high-dimensional data in randomised clinical trials: A review of methods and practice

  2023cites this paper
• Sleep quality and predictors of optimal sleep in patients with rheumatoid arthritis: data from a recent-onset cohort.

  2023cites this paper
• MTHFR c.665C>T and c.1298A>C Polymorphisms in Tailoring Personalized Anti-TNF-α Therapy for Rheumatoid Arthritis

  2023cites this paper
• Molecular signature of methotrexate response among rheumatoid arthritis patients

  2023cites this paper
• Heterogeneity of treatment responses in rheumatoid arthritis using group based trajectory models: secondary analysis of clinical trial data

  2023cites this paper
• Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials

  2023cites this paper
• Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors

  2023cites this paper
• Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis

  2023cites this paper
• Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR

  2023cites this paper
• The Complement System in Spondyloarthritis: What Do We Know?

  2022cites this paper
• Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

  2022cites this paper
• COVID-19 among Rheumatoid Arthritis Patients on ‎Immunosuppressive Therapy During the First Wave of the COVID-‎‎19 Pandemic: a Prospective Comparative Study ‎

  2022cites this paper
• Associations between microRNA-related genetic polymorphisms and clinical response to methotrexate in Chinese rheumatoid arthritis patients.

  2022cites this paper
• Analysis of Association between Interleukin-6 (<i>IL</i>6), Interleukin-13 (<i>IL</i>13) and Tumor Necrosis Factor-Alpha (<i>TNF-alpha</i>) Gene Polymorphisms and Genetic Susceptibility of Rheumatoid Arthritis in Kuwaiti Arab

  2022cites this paper
• Seropositivity-Dependent Association between LINE-1 Methylation and Response to Methotrexate Therapy in Early Rheumatoid Arthritis Patients

  2022cites this paper
• Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis.

  2022cites this paper
• Impact of disease burden or inflammation on nutritional assessment by the GLIM criteria in female patients with rheumatoid arthritis.

  2022cites this paper
• Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

  2022cites this paper
• Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis

  2022cites this paper
• Add-on Effectiveness of Methotrexate or Iguratimod in Patients with Rheumatoid Arthritis Exhibiting an Inadequate Response to Janus Kinase Inhibitors: The ANSWER Cohort Study.

  2022cites this paper
• Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control.

  2022cites this paper
• -Omic Approaches and Treatment Response in Rheumatoid Arthritis

  2022cites this paper
• Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis

  2022cites this paper
• Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs

  2022cites this paper
• Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes

  2022cites this paper
• Safety and Effectiveness of Certolizumab Pegol in Japanese Patients with Rheumatoid Arthritis: Results from a 24-Week Post-Marketing Surveillance Study.

  2022cites this paper
• A Comparison of EQ-5D-3L, EQ-5D-5L, and SF-6D Utilities of Patients with Musculoskeletal Disorders of Different Severity: A Health-Related Quality of Life Approach

  2022cites this paper
• MALT1 regulates Th2 and Th17 differentiation via NF-κB and JNK pathways, as well as correlates with disease activity and treatment outcome in rheumatoid arthritis

  2022cites this paper
• The Bioimpedance Phase Angle may be Associated With Frailty in Rheumatoid Arthritis Patients: Results From a Prospective, Cohort Study.

  2022cites this paper
• EULAR 75-year anniversary: commentaries on ARD papers from 25 years ago

  2022cites this paper
• The bioimpedance phase angle is more useful than sarcopenia as a predictor of falls in patients with rheumatoid arthritis: Results from a 2-y prospective cohort study.

  2022cites this paper
• Increase of Circulating Monocyte–Platelet Conjugates in Rheumatoid Arthritis Responders to IL-6 Blockage

  2022cites this paper